Currently there is no specific treatment approved for monkeypox virus infections. However, antivirals developed for use in patients with smallpox may prove beneficial. The following medical countermeasures are currently available from the Strategic National Stockpile (SNS) as options for the treatment of monkeypox:
- Approved by the FDA (PDF) for the treatment of smallpox in adults and children weighing at least 6.6 pounds.
- CDC holds a special permit that allows for the use of tecovirimat to treat monkeypox during an outbreak.
- Available as a pill or an injection.
- For children who weigh less than 28.6 pounds, the capsule can be opened and medicine mixed with semi-solid food.
- Approved by the FDA (PDF) for the treatment of cytomegalovirus (CMV) retinitis in patients with Acquired Immunodeficiency Syndrome (AIDS).
- CDC holds an Expanded Access Investigational New Drug (EA-IND) Protocol status that allows for the use of Cidofovir for the treatment of orthopoxviruses (including monkeypox) in an outbreak.
Vaccinia Immune Globulin Intravenous (VIGIV):
- Licensed by FDA for the treatment of complications due to vaccinia vaccination including eczema vaccinatum, progressive vaccinia, severe generalized vaccinia, vaccinia infections in individuals who have skin conditions, and aberrant infections induced by vaccinia virus (except in cases of isolated keratitis).
- CDC holds an EA-IND that allows the use of VIGIV for the treatment of orthopoxviruses (including monkeypox) in an outbreak.
- Antiviral medication
- Approved by the FDA (PDF) on June 4, 2021 for the treatment of human smallpox disease in adult and pediatric patients, including neonates.
- CDC is currently developing an EA-IND to help facilitate use of Brincidofovir as a treatment for monkeypox.
- However, Brincidofovir is not currently available from the SNS.
State and territorial health authorities can direct their requests for medical countermeasures for the treatment of monkeypox to the CDC Emergency Operations Center (770-488-7100).